CLINUVEL

Bell Potter Healthcare Conference

14-16 November 2023

ASX	CUV
Börse Frankfurt	UR9
Level 1 ADR	CLVLY

CLINUVEL GROUP

Forward-looking statement

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2023 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

The technology – melanocortins



Active fragments	**– melanocortins**
His^{6}-Phe^{7}-Arg^{8}-Trp^{9}	**– melanogenesis**
Pro^{11}- Lys^{12}-Val^{13}	**– anti-inflammatory**
Afamelanotide	**– NLe^{4}-DPhe^{7}-α-MSH** **– hydrogen bond TM2**

COMPANY	YEAR*	RECEPTOR/S	STATUS
Merck	1999	MC4R	Abandoned
Basilea	2003	MC4R	Abandoned
Abbvie	2008	MC1R, MC3R, MC4R, MC5R	Abandoned
Novo Nordisk	2014	MC4R	Abandoned
Zengen	2007	MC1R	Abandoned
Aequus Bio.	2016	MC3R, MC4R	Research
U. Cincinnati (Abdel Malek)	2006	MC1R	Research
MC1R Ventures	2022	MC1R	Undisclosed
Crinetics Pharm.	2019	MC2R	Phase II
Santhera	2009	MC4R	Phase II
Synact	2015	MC1R, MC4R	Phase II
Mallinckrodt	1952	MC1R-MC5R	Chapter 11, ACTH
IPSEN	2007	MC4R	Licensed to Rhythm
Amphastar	1952	MC2R	Approved (sNDA): ACTH
ANI Pharma	1952	MC2R	Approved (sNDA): ACTH
Palatin Technology	1986	MC1R	Approved: HSDD
Rhythm Pharma	2008	MC4R	Approved: obesity/BBS
CLINUVEL	**1987**	**MC1R, MC3R, MC4R**	**Approved: afamelanotide** **In dev: ACTH, small molecule**

BBS: Bardet-Biedl syndrome | HSDD: hypoactive sexual desire disorder | ACTH: adrenocorticotropic hormone | * Year of initial development

Pharmaceutical pipeline



XP; xeroderma pigmentosum | IS; infantile spasms | MS; multiple sclerosis | CNS; central nervous system.

PhotoCosmetics

CYACÊLLE
Polychromatic screen



CYACÊLLE
Radiant

Identity & visibility
- architecture
- launch events 2024-25-26

Advocacy
- CUVA (60)
- CUVIP (10)
- social media

Digital Campaigns
- multi-channel
- new digital platform
- cost of customer acquisition
- click through rate (target 3.2%)
- conversion rate (1.8-2.3%)

Distribution
- medical
- e-commerce
- high-end retail

Total addressable market (sunless tanning)
US$6.2B
Penetration yr 1-5: 1% = US$60M

Multiple catalysts

Next 12 months	
SCENESSE®	**use in adolescents – EMA guidance** **regulatory filing Canada**
Vitiligo	**CUV105, n=200 – complete recruitment** **CUV107, n=200**
XP – DNA Repair	**CUV151-156 readouts** **CUV154-158 study start**
VP	**CUV040 – study complete**
CNS disorders	**CUV803 – readouts (PRÉNUMBRA®)** **new indication – study start**
NEURACTHEL®	**manufacturing progress**
PhotoCosmetics	**website launch; e-commerce** **CYACÊLLE global launch events**
Finances	**earnings growth**



Building a melanocortin house



Thank you for your attention

Bell Potter Healthcare Conference

14-16 November 2023

ASX	CUV
Börse Frankfurt	UR9
Level 1 ADR	CLVLY